Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.67 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.65 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.65 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.65 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.65 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.65 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.65 |
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.65 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.65 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263420 | 1.00 | CA5A (0.67) | CA5AP2RY1TAS1R3TAS1R1P2RY11 | |
| SCHEMBL263421 | 1.00 | CA5A (0.67) | CA5AP2RY1TAS1R3TAS1R1P2RY11 | |
| SCHEMBL17010791 | 1.00 | CA5A (0.67) | CA5AP2RY1TAS1R3TAS1R1P2RY11 | |
| SCHEMBL309060 | 0.93 | P2RY1 (0.71) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL625113 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL20901220 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL14928757 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL14948858 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL19442379 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 | |
| SCHEMBL14853693 | 0.92 | P2RY1 (0.72) | P2RY1P2RY11SRCP2RY2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | CA5A 3364/4885P2RY1 3103/4885TAS1R3 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.